Evaluation of Antioxidant and Anti Parkinsonism Activity of Betaine in Experimental Rats
Aim and Objectives: The present study was aimed to evaluate anti parkinsonium effect of Betaine for its Applications in trigger factors in pathogenesis of Parkinson’s disease and to understand development of new treatments approaches for PD. Betaine is naturally obtained product. It has antioxidant, neuroprotective activity. Hence, we inspected whether betaine can act as a protective agent in 6-OHDA induced oxidative stress on cerebellum of Sprague-Dawleyrats.
Material and Methods Thirty-six adult Sprague-Dawley rats were dived into six groups. Rats were received unilateral 6- hydroxydopamine lesions for induction except normal and rats were treated with respective treatment. At the day of 21 rats were sacrificed. Prepared brain homogenate was used for further Biochemical estimation.
Result: Betaine showed marked rise in SOD and Catalase activity as well as GSH content subsequently decreasing in the lipid peroxidation process. Our result suggests Betaine to be potent antioxidant at dose 12.5 and 25 mg/kg as compared to standard (L-dopa+Benserazide) and pro-inflammatory cytokines viz: TNF-α, IL-1β and IL-6 were significantly reversed by Betaine as compared to that of standard group (L-dopa+ Benserazide).
Discussion and Conclusion: Betaine showed dose dependent effect by reducing LPO level as increasing SOD, GSH and Catalase activity and marked reduced proinflammatory cytokine, hence we conclude that betaine has good anti parkinsonism activity.
Keywords: 6-OHDA, Antioxidant, Betaine, Pro-inflammatory cytokines.
2. De Lau LM, Breteler MM, Epidemiology of Parkinson's disease. The Lancet Neurology, 2006; 5(6):525-535.
3. Lundblad M, Anderson M, Winkler C, Kiric D, Wierup N, Cenci M, Pharmcolological validation of behavioural measures of akinesia and dyskinesia in rat model parkinson’s disease. European Journal of Neuroscience, 2002; 15:120-32.
4. Goes AT, Jesse CR, Antunes MS, Ladd FVL, Ladd AAL, Luchese C, Paroul N, Boeira SP, Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson's disease: Involvement of neuroinflammation and neurotrophins. Chemico-biological interactions, 2018; 279:111-120.
5. Lai CL, Lu CC, Lin HC, Sung YF, Wu YP, Hong JS, Peng GS, Valproate is protective against 6-OHDA-induced dopaminergic neurodegeneration in rodent midbrain: A potential role of BDNF up-regulation. Journal of the Formosan Medical Association, 2019; 118(1):420-428.
6. Craig S, Betaine in human nutrition, American Journal of Clinical Nutrition, 2004; 80:539–49
7. Alirezaei M, Khoshdel Z, Dezfoulian O, Rashidipour M, Taghadosi V, Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats’. Journal of Physiology and Science 2015; 65:243-52.
8. Alirezaei M. Betaine protects cerebellum from oxidative stress followinglevodopa and benserazide administration in rats’. IJBMS 2004; 18:950-957.
9. Alirezaei M, Jelodar G, Niknam P, Ghayemi Z, Nazifi S, Betaine prevents ethanol-induceed stress and reduce total homocysteine in the rat cerebellum Journal of Physiology and Biochemistry 2011; 67:605-612.
10. Lawson A, Levy H, The use of betaine in the treatment of elevated homocysteine, Molecular Genet Metabolism Report 2006; 88:201-07.
11. Zhang H, Liqun M, Chen J, Zhen X, Chronic SKF 83959 Include less sever dyskinesia and attenuated L-DOPA induced dyskinesia in 6-OHDA lesioned rat model of Parkinson’s disease’. Journal Neuropharmacy 2007; 53:125-33.
12. Eskow K, Gupta V, Alam S, Park J, Bishop C, The partial 5-HT1A agonist buspirone reduces the expression and development of L-DOPA induced dyskinesia in rats and improves L-DOPA efficacy’. Pharmacology and Biochemistry Behaviour 2007; 87:306–314.
13. Bishop C, Taylor J, Ullrich T, Kuhn D, Eskow K, Park J, Walker P, MDMA and fenfluramine reduce L-DOPA induced dyskinesia via indirect 5-HT1A receptor Stimulation European Journal of Neuroscience 2006; 23:2669-76.
14. Matheus F, Rial D, Real J, Lemos C, Ben J, Guaita G, Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats’. Behav Brain Research 2015; 301:43-54.
15. Sadekar S, Chauhan V, Shirole R, Salve B, Kasture S, Antidopaminergic activity of VitexnegundoLinn leaves Journal of Natural Remedies 2006; 6(2):165–69.
16. Jain PG, Mahajan UB, Shinde SD, Surana SJ, Cardioprotective role of FA against isoproterenol induced cardiac toxicity. Molecular biology reports, 2018; 45(5):1357-1365.
17. Sonawane VK, Mahajan UB, Shinde SD, Chatterjee S, Chaudhari SS, Bhangale HA, Ojha S, Goyal SN, Kundu CN, Patil CR, A chemosensitizer drug: Disulfiram prevents doxorubicin-induced cardiac dysfunction and oxidative stress in rats. Cardiovascular toxicology, 2018; 18(5):459-470.
18. Khairnar SI, Mahajan UB, Patil KR, Patel HM, Shinde SD, Goyal SN, Belemkar S, Ojha S, Patil CR, Disulfiram and Its Copper Chelate Attenuate Cisplatin-Induced Acute Nephrotoxicity in Rats Via Reduction of Oxidative Stress and Inflammation. Biological trace element research, 2019; 2:1-11.
19. Nair V, Arjuman A, Dorababu P, Gopalkrishna H, Chakradhar-rao U, Mohan L, Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice Indian Journal of Medical Research, 2007; 126:480-84.
20. Deumens R, Blokland A, Prickaerts J, Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp Neurol 2002; 175:303-17.
21. Schober A, Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP Cell Tissue Research 2004;318:215-24.
22. Gopal krishna C, Shankarnarayan D, Nazimudeen Sk, Kameswara L, Effect of tylophorine, a major alkaloid of Tylophoraindica, on immunopathological and inflammatory reactions. ijmr 2008; 71:940-48.
23. Zbarsky V, Datla P, Parkar S, Rai K, Aruoma I, Dexter T. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease Free Radical Research 2005;39:1119-25.
24. Reale A, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M, Peripheral cytokines profile in Parkinson’s disease Brain, Behavioural Immunology 2009; 23:55–63.
25. Qin L, Wu X, Block L, Liu Y, Breese R, Hong J, Knapp J, Crews T, Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration, Glia 2007; 55:453–62.
26. Iarlori C, Reale M, Lugaresi A, Luca G, Bonanni L, Di Iorio A, Feliciani C, Conti P, Gambi D, RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b, Journal Neuroimmunology, 2000; l107:100–07.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).